Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

5-HT3/NK1 antagonist combination effective in emesis treatment and prevention

July 26, 1996

Vanderbilt University describes ligands for 5-HT3 receptors

July 26, 1996

MBP peptide analogues described as multiple sclerosis treatment

July 26, 1996

Yeda claims protein as potential autoimmune disease treatment

July 26, 1996

Chinoin describes new selegiline formulation

July 26, 1996

Raloxifene indicated for excess NPY associated disorders

July 26, 1996

Pierre Fabre reports 5-HT1A agonists

July 26, 1996

Duloxetine claimed for new indication

July 26, 1996

Positive safety profile reported on histamine H3 antagonist research

July 26, 1996

SEPA-ibuprofen formulation fares well in phase II trial

July 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...